Copyright
©The Author(s) 2016.
World J Gastroenterol. Nov 21, 2016; 22(43): 9613-9622
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9613
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9613
Table 1 Sustained virologic response according to patient characteristics at baseline (n = 288) n (%)
Achieved SVR | P value | ||
Yes (n = 237) | No (n = 51) | ||
Demographics | |||
Sex | |||
Male | 101 (87.1) | 15 (12.9) | 0.081 |
Female | 136 (79.1) | 36 (20.9) | |
Age | |||
Mean ± SD | 45.9 ± 10.4 | 50.1 ± 8.5 | 0.007 |
Median (range) | 48.00 (11.0-68.0) | 49.00 (34.0-66.0) | 0.016 |
≤ 20 | 5 (100) | 0 (0) | 0.017 |
21-40 | 57 (87.7) | 8 (12.3) | |
41-60 | 164 (82.4) | 35 (17.6) | |
> 60 | 11 (57.9) | 8 (42.1) | |
Pretreatment conditions/comorbidities | |||
HCV/HIV coinfection | 4 (100) | 0 (0) | 0.350 |
Diabetes mellitus | 21 (91.3) | 2 (8.7) | 0.238 |
Previous alcohol consumption | 45 (81.8) | 10 (18.2) | 0.919 |
High pretreatment ALT (> 40) | 166 (81.8) | 37 (18.2) | 0.722 |
High pretreatment Hgb (≥ 12 g/dL) | 182 (81.3) | 42 (18.8) | 0.386 |
High pretreatment WBC (≥ 4000 mm3) | 225 (82.7) | 47 (17.3) | 0.432 |
High pretreatment platelet (≥ 150000/mm3) | 189 (84.8) | 34 (15.2) | 0.043 |
High pretreatment albumin (≥ 3.5 g/dL) | 212 (84.5) | 39 (15.5) | 0.012 |
High pretreatment HCV RNA (≥ 800000 IU/mL) | 144 (79.1) | 38 (20.9) | 0.065 |
Liver stiffness | |||
F ≤ 2 | 133 (92.4) | 11 (7.6) | < 0.001 |
F3-4 | 104 (72.2) | 40 (27.8) | |
IL-28B polymorphism | |||
rs8099917TT | 204 (82.3) | 44 (17.7) | 0.634 |
rs8099917Non-TT | 18 (78.3) | 5 (21.7) | |
Unknown | 15 (88.2) | 2 (11.8) | |
rs12979860CC | 196 (82.4) | 42 (17.6) | 0.618 |
Table 2 Sustained virologic response by treatment modifications and hepatitis C virus genotype (n = 288) n (%)
Achieved SVR | P value | ||
Yes(n = 237) | No(n = 51) | ||
Dose reduction | |||
Any dose reduction | 43 (79.6) | 11 (20.4) | 0.570 |
Peg-IFN only | 9 (100) | 0 (0) | 0.157 |
Ribavirin only | 12 (70.6) | 5 (29.4) | 0.193 |
Both peg-IFN and ribavirin | 22 (78.6) | 6 (21.4) | 0.587 |
Genotype | |||
1 | 42 (75.0) | 14 (25.0) | 0.314 |
2 | 4 (100) | 0 (0) | |
3 | 123 (84.8) | 22 (15.2) | |
6 | 68 (81.9) | 15 (18.1) |
Table 3 Sustained virologic response according to fibrosis score and genotype (n = 288) n (%)
Total patients | F ≤2 (n = 144) | F 3-4 (n = 144) | P value | |||
SVR+ | SVR- | SVR+ | SVR- | |||
All genotypes | 288 | 133 (46) | 11 (4) | 104 (36) | 40 (14) | 0.034 |
Genotype 1 | 56 | 26 (46) | 3 (5) | 16 (29) | 11 (20) | 0.009 |
Genotype 2 | 4 | 0 (0) | 0 (0) | 4 (100) | 0 (0) | |
Genotype 3 | 145 | 60 (41) | 4 (3) | 63 (43) | 18 (12) | 0.008 |
Genotype 6 | 83 | 47 (57) | 4 (5) | 21 (25) | 11 (13) | 0.002 |
Table 4 Relapse according to patient characteristics at baseline (n = 283) n (%)
Relapse (n = 49) | No relapse (n = 234) | P value | |
Relapse | 49 (17.3) | 234 (82.7) | |
Demographics | |||
Sex | |||
Male | 14 (12.4) | 99 (87.6) | 0.074 |
Female | 35 (20.6) | 135 (79.4) | |
Age | |||
mean ± SD | 50.4 ± 8.5 | 46.0 ± 10.2 | 0.006 |
Median (range) | 50.00 (34.0-66.0) | 48.00 (11.0-68.0) | 0.011 |
≤ 20 | 0 (0) | 4 (100) | 0.013 |
21-40 | 7 (10.9) | 57 (89.1) | |
41-60 | 34 (17.3) | 162 (82.7) | |
> 60 | 8 (42.1) | 11 (57.9) | |
Pre-treatment/comorbidities | |||
HCV/HIV coinfection | 0 (0) | 3 (100) | 0.426 |
Diabetes mellitus | 2 (8.7) | 21 (91.3) | 0.254 |
Previous alcohol consumption | 9 (17.0) | 44 (83.0) | 0.943 |
High pretreatment ALT (> 40) | 36 (17.9) | 165 (82.1) | 0.678 |
High pretreatment Hgb (≥ 12g/dL) | 40 (18.3) | 179 (81.7) | 0.434 |
High pretreatment WBC (≥ 4000 mm3) | 45 (16.9) | 222 (83.1) | 0.403 |
High pretreatment platelet (≥ 150000/mm3) | 32 (14.7) | 186 (85.3) | 0.032 |
High pretreatment albumin (≥ 3.5 g/dL) | 37 (15.0) | 209 (85.0) | 0.009 |
High pretreatment HCV RNA (≥ 800000 IU/mL) | 36 (20.3) | 141 (79.7) | 0.082 |
Liver stiffness | |||
F ≤ 2 | 9 (6.5) | 130 (93.5) | < 0.001 |
F3-4 | 40 (27.8) | 104 (72.2) | |
IL28B polymorphism | |||
rs8099917TT | 42 (17.3) | 201 (82.7) | 0.592 |
rs8099917Non-TT | 5 (21.7) | 18 (78.3) | |
Unknown | 2 (11.8) | 15 (88.2) | 0.918 |
rs12979860CC | 40 (17.2) | 193 (82.8) | 0.569 |
Table 5 Relapse by treatment modifications and hepatitis C virus genotype (n = 283) n (%)
Relapse Yes | Relapse No | P value | |
(n = 49) | (n = 234) | ||
Dose reduction | |||
Any dose reduction | 10 (19.2) | 42 (80.8) | 0.686 |
Peg-IFN only | 0 (0) | 9 (100) | 0.163 |
Ribavirin only | 4 (26.7) | 11 (73.3) | 0.325 |
Both peg-IFN and ribavirin | 6 (21.4) | 22 (78.6) | 0.544 |
Genotype | |||
1 | 14 (25.0) | 42 (75.0) | 0.279 |
2 | 0 (0) | 4 (100) | |
3 | 21 (14.7) | 122 (85.3) | |
6 | 14 (17.5) | 66 (82.5) |
Table 6 Preliminary analysis of sustained virologic response outcome by treatment duration and prognostic baseline factors in patients with genotype 3 hepatitis C virus infection
Comparison or stratum | OR (95%CI) | P value |
Age | 1.02 (0.97-1.08) | 0.432 |
Liver fibrosis (F3-4 vs F ≤ 2) | 0.18 (0.05-0.67) | 0.010 |
Sex (female vs male) | 0.41 (0.14-1.16) | 0.093 |
Treatment duration (48 wk vs 24 wk) | 2.05 (0.42-9.92) | 0.371 |
Table 7 Sustained virologic response outcome by prognostic baseline factors in patients with genotypes 1, 3, and 6 hepatitis C virus infection
Comparison or stratum | OR (95%CI) | P value |
Age | 1.00 (0.96-1.04) | 0.904 |
Genotype (1 vs 6) | 0.74 (0.30-1.84) | 0.433 |
Genotype (3 vs 6) | 1.33 (0.58-3.05) | 0.433 |
High pretreatment HCV RNA (≥ 800000 IU/mL) | 0.42 (0.19-0.92) | 0.029 |
High pretreatment albumin (≥ 3.5 g/dL) | 2.63 (1.11-6.22) | 0.028 |
High pretreatment platelet (≥ 150000/mm3) | 1.00 (0.45-2.25) | 0.992 |
Liver fibrosis (F3-4 vs F ≤ 2) | 0.19 (0.08-0.48) | < 0.001 |
Sex (female vs male) | 0.57 (0.28-1.16) | 0.120 |
Treatment duration (48 wk vs 24 wk)1 | 2.05 (0.42-9.92) | 0.371 |
Table 8 Adverse events and treatment modifications (n = 288) n (%)
48 wk treatment (n = 162) | 24 wk treatment (n = 126) | |
Dose reduction | ||
Any dose reduction | 34 (21.0) | 20 (15.9) |
Peg-IFN only | 3 (1.9) | 6 (4.8) |
Ribavirin only | 13 (8.0) | 4 (3.2) |
Both peg-IFN and ribavirin | 18 (11.1) | 10 (7.9) |
Hematological adverse events | ||
Hemoglobin reduction = 1.5 g/dL from pretreatment value | 121 (74.7) | 85 (67.5) |
Erythropoietin use | 99 (61.1) | 62 (49.2) |
Severe anemia (Hgb < 7 g/dL) | 4 (2.5) | 3 (2.4) |
WBC < 4000 cells/mm3 | 110 (67.9) | 86 (68.3) |
Platelet reduction < 150000 cells/mm3 | 75 (46.3) | 72 (57.1) |
General adverse events | ||
Fatigue | 115 (71) | 89 (70.6) |
Poor appetite | 92 (56.8) | 82 (65.1) |
Itchiness | 16 (9.9) | 11 (8.7) |
Skin rash | 5 (3.1) | 0 (0) |
Joint pain | 20 (12.3) | 13 (10.3) |
Myalgia/muscle aches | 9 (5.6) | 8 (6.3) |
Hair loss | 34 (21) | 17 (13.5) |
Dizziness | 36 (22.2) | 31 (24.6) |
Insomnia | 63 (38.9) | 49 (38.9) |
Irritability | 5 (3.1) | 2 (1.6) |
Depression | 13 (8.0) | 5 (4.0) |
Thyroid dysfunction | 7 (4.3) | 1 (0.8) |
- Citation: Hlaing NKT, Banerjee D, Mitrani R, Arker SH, Win KS, Tun NL, Thant Z, Win KM, Reddy KR. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country. World J Gastroenterol 2016; 22(43): 9613-9622
- URL: https://www.wjgnet.com/1007-9327/full/v22/i43/9613.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i43.9613